Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jonathan Thon
AddedMar 31, 2024
UpdatedMay 31, 2026
Jonathan Thon

Jonathan Thon

Founder, Strm.Bio

CrunchbaseLinkedIn

Jonathan Thon's Career

Strm.Bio
Strm.Bio

Cambridge, MA, US

Founder
Platelet BioGenesis
Platelet BioGenesis

Watertown, MA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jonathan Thon's Career

Strm.Bio
Strm.Bio
Seed$2.1M192019Cambridge, MA, US
Founder

Similar to Strm.Bio

StrideBioStrideBioDurham, NC, USGene Therapyest. 2015StrideBioDurham, NC, US · est. 2015

StrideBio, Inc. is a US-based gene therapy company, specializing in genetic medicines for rare monogenic diseases.

Series B · $97.2M76
Carmine TherapeuticsCarmine TherapeuticsCambridge, MA, USGene Therapiesest. 2019Carmine TherapeuticsCambridge, MA, US · est. 2019

Carmine Therapeutics: Pioneering non-viral gene therapies via red blood cell vesicles.

Series A · $3.4M39
Exegenesis BioExegenesis BioLansdale, PA, USGene Therapyest. 2019Exegenesis BioLansdale, PA, US · est. 2019

Exegenesis: A global leader in gene therapy, innovating new medicines for China and worldwide.

Series B · $10M17
Mantra BioMantra BioSan Francisco, CA, USMedicines, Therapeuticsest. 2016Mantra BioSan Francisco, CA, US · est. 2016

Mantra Bio: Harnessing exosomes for safe, targeted therapeutic delivery.

Series A · $34M42
Platelet BioGenesis
Platelet BioGenesis
Series B$132.1M392014Watertown, MA, US
Co-Founder

Leadership at Platelet BioGenesis

Sven KarlssonSven KarlssonCo-Founder
Derek AdamsDerek AdamsCEO
Joseph ItalianoJoseph ItalianoCo-Founder
Mark McDadeMark McDadeBoard Member
Steven M. AltschulerSteven M. AltschulerBoard Member
Richard MurrayRichard MurrayBoard Member

Similar to Platelet BioGenesis

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
Alloplex BiotherapeuticsAlloplex BiotherapeuticsBoston, MA, USCellular Therapiesest. 2016Alloplex BiotherapeuticsBoston, MA, US · est. 2016

Alloplex Biotherapeutics, a Boston-based firm, develops broad-spectrum, tumor-agnostic cellular therapies.

Series A · $21.2M5
AlloCureAlloCureBurlington, MA, USCell Therapiesest. 2008AlloCureBurlington, MA, US · est. 2008

AlloCure, Inc.: A US-based biotech firm specializing in cell therapies for kidney diseases.

Series B · $47M11

Jonathan Thon's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Jonathan Thon

David RaiserDavid RaiserBoard Member · Aldatu BiosciencesManuel RamirezManuel RamirezCo-Founder · InbifyRichard JhangRichard JhangCEO · StrλtmindsAkhil LodhaAkhil LodhaCo-Founder · Sliced InvestingJon StenstromJon StenstromCo-Founder · CrixlabsDoug DanielsDoug DanielsFounder · Dogma Therapeutics